Lobbying disclosures · Lobbying report
TECH: second_quarter 2026 lobbying report
A lobbying activity report was filed. Income and expenses are separate reporting measures and must not be added together.
Follow TECH- Became public
- Jul 16, 2026, 10:09 AM EDT
- Event / period date
- Not stated
- Collected
- Nov 9, 2026, 10:38 PM EST
Why this is connected
Legal-name match: BIO-TECHNE CORPORATION is BIO-TECHNE Corp (https://www.sec.gov/Archives/edgar/data/842023/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/3ef504f7-7787-46c2-b853-3e1ad9464a84/","filing_uuid":"3ef504f7-7787-46c2-b853-3e1ad9464a84","filing_type":"Q2Y","filing_type_display":"2nd Quarter - Report (No Activity)","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/3ef504f7-7787-46c2-b853-3e1ad9464a84/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Glenn Willard, Of Counsel","dt_posted":"2026-07-16T10:09:09-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2550 M STREET, NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20037","registrant":{"id":30906,"url":"https://lda.gov/api/v1/registrants/30906/","house_registrant_id":31917,"name":"SQUIRE PATTON BOGGS","description":"Law Firm","address_1":"2550 M STREET, NW","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20037","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GLENN WILLARD","contact_telephone":"+1 202-457-6000","dt_updated":"2026-07-10T16:40:57.961456-04:00"},"client":{"id":58284,"url":"https://lda.gov/api/v1/clients/58284/","client_id":58284,"name":"BIO-TECHNE CORPORATION","general_description":"Provide high-quality reagents, instruments, custom manufacturing, and testing services.","client_government_entity":null,"client_self_select":false,"state":"MN","state_display":"Minnesota","country":"US","country_display":"United States of America","ppb_state":"MN","ppb_state_display":"Minnesota","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-11-13"},"lobbying_activities":[],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in TECH
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- May 6, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded Apr 8, 2026 · disclosed May 6, 2026 · Dependent
- Apr 6, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
Sold (partial) Bio-Techne TECH
$1K–$15K · Traded Mar 26, 2026 · disclosed Apr 6, 2026 · Dependent
- Mar 10, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
Sold (partial) Bio-Techne TECH
$1K–$15K · Traded Feb 24, 2026 · disclosed Mar 10, 2026 · Dependent
- Feb 2, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
Sold (partial) Bio-Techne TECH
$1K–$15K · Traded Jan 28, 2026 · disclosed Feb 2, 2026 · Dependent
- Jan 5, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded Dec 5, 2025 · disclosed Jan 5, 2026 · Dependent
- Jan 5, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded Dec 2, 2025 · disclosed Jan 5, 2026 · Dependent
- Nov 4, 2025$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded Oct 22, 2025 · disclosed Nov 4, 2025 · Dependent
- Sep 2, 2025$1K–$15K
Rep. April McClain Delaney (D-MD-6)
Sold (partial) Bio-Techne TECH
$1K–$15K · Traded Aug 1, 2025 · disclosed Sep 2, 2025 · Dependent
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.